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ABSTRACT
Introduction Knee pain due to osteoarthritis (OA) is a 
common cause of disability. The UK National Institute for 
Health and Care Excellence OA guidelines recommend 
education, exercise and weight loss advice (if overweight) 
as core interventions before pharmacological adjuncts. 
However, implementation of these in primary care 
is often suboptimal. This study aims to develop a 
complex intervention with non- pharmacological and 
pharmacological components that can be delivered by 
nurses. The feasibility and acceptability of the intervention, 
and feasibility of undertaking a future cohort randomised 
controlled trial (RCT) will be explored.
Methods and analysis In phase 1, we will develop a 
training programme for nurses and evaluate the fidelity 
and acceptability of the non- pharmacological element of 
the intervention. Fidelity checklists completed by the nurse 
will be compared with video analysis of the treatment 
sessions. Patients and nurses will be interviewed to 
determine the acceptability of the intervention and 
explore challenges to intervention delivery. The non- 
pharmacological component will be modified based on 
the findings. In phase 2, we will assess the feasibility 
of conducting a cohort RCT comprising both the 
pharmacological and modified non- pharmacological 
components. We will compare three groups: group A will 
receive the non- pharmacological components delivered 
before pharmacological components; group B will receive 
pharmacological components followed by the non- 
pharmacological components; and group C (control arm) 
will continue to receive usual care. Study outcomes will 
be collected at three time points: baseline, 13 and 26 
weeks after randomisation. Qualitative interviews will be 
conducted with a sample of participants from each of the 
two active intervention arms.
Ethics and dissemination This protocol was approved 
by the East Midlands- Derby Research Ethics Committee 
(18/EM/0288) and registered at  ClinicalTrials. gov 
(protocol v4.0, 10/02/2020). The study will be reported 
in accordance with the Consolidated Standards of 
Reporting Trials guidance and standards. The results will 
be submitted for publication in peer- reviewed academic 
journals.
Trial registration number NCT03670706
INTRODUCTION
Chronic knee pain affects one in four people 
aged 55 years or older, and is most commonly 
caused by osteoarthritis (OA).1 The global 
prevalence of symptomatic knee OA is esti-
mated at 4%, and it has an important impact 
on both affected individuals and health and 
social care systems.2 3 The socioeconomic 
and healthcare burden of knee OA is likely 
to increase due to the ageing population and 
the obesity epidemic.2 4
Best practice guidelines for managing OA 
published by the National Institute for Health 
and Care Excellence (NICE) recommend 
individualised patient education, advice 
Strengths and limitations of this study
 ► First study to develop and evaluate the feasibility of 
a wholly nurse- led intervention following the core 
National Institute for Health and Care Excellence 
guidelines for treating knee pain and osteoarthritis 
(OA).
 ► This study will not determine the effectiveness of 
this model of care for knee pain and OA, but will 
explore the feasibility of implementation and running 
an adequately powered randomised controlled trial 
(RCT) and determine signal of efficacy.
 ► Assessing fidelity of intervention delivery will allow 
us to explore the extent to which the nurses can de-
liver individual components of the complex package 
of care as planned, and alongside exploring its ac-
ceptability will inform refinements to nurse training 
and/or the package of care.
 ► Blinded outcome assessment.
 ► Participants and nurses delivering care will not be 
blinded to each intervention. However, in using a 
cohort RCT study design where participants will be 
informed that their data may be used as a control 
comparison for intervention studies, bias associat-
ed with disappointment, behaviour modification and 
dropouts in the control arm will be minimised.
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and access to information about OA and its manage-
ment, strengthening and aerobic exercise, and guidance 
on losing weight if applicable as core treatments, with 
consideration of adjunctive pharmacological and other 
non- pharmacological treatments as required.5 However, 
core treatments are frequently underused as both doctors 
and patients predominantly focus on pharmacological 
options including opioids.6 7 Most people with OA feel 
they do not receive the treatment they need from general 
practitioners (GP), with an overemphasis on prescription 
drugs and lack of discussion about exercise and diet.8 
Given the growing concerns about the overuse of opioids 
for musculoskeletal pain including OA,9 it is important to 
explore alternative models of healthcare delivery with an 
emphasis on non- pharmacological interventions for this 
condition. Additionally, while it has been suggested that 
optimising analgesia prior to participation in exercise 
therapy may enhance adherence and patient outcomes, 
this has not been confirmed in a randomised controlled 
trial (RCT).10
Alternative models for implementing OA care have 
shown potential. The MOSAICS trial explored the effec-
tiveness of delivering an enhanced initial consultation 
with GP and provision of nurse- led follow- ups as a clin-
ically practicable way of implementing NICE guidelines 
compared with usual care.11 However, only 29% of patients 
in the intervention arm reported having a consultation 
with a nurse, making it difficult to determine whether a 
nurse could help deliver the core NICE recommenda-
tions. Others have included using community physio-
therapists and pharmacists for delivering interventions 
but have only demonstrated short- term improvements in 
health outcomes.12
The majority of patients with knee pain self- manage 
their symptoms, and those who seek healthcare are 
managed by their GPs and community physiotherapists 
in the first instance.8 A potential role for practice nurses 
has been identified13 and nurse- led clinics already exist 
for patients with long- term conditions such as coronary 
heart disease,14 heart failure15 and diabetes16 resulting in 
equivalent or better outcomes for patients compared with 
usual GP- led care. Upskilling practice nurses to deliver 
the management of long- term conditions is recognised as 
a key strategy for the future of primary care.17 This paper 
describes the protocol for developing and testing the feasi-
bility of a wholly nurse- led intervention for people with 
knee pain, delivering the core NICE recommendations.
Further to this, it will test the feasibility of a cohort RCT. 
The usual double- blind, placebo- controlled RCT cannot 
be used when investigating the efficacy of complex 
interventions for knee pain as it is not possible to blind 
participants to their treatment. This has led to the use 
of pragmatic RCTs where participants are randomised 
to receive an intervention or continue usual primary 
care.12 18 Such studies can be affected by disappoint-
ment bias, behaviour modification bias and differential 
dropouts when those selected as controls had hoped to 
receive the intervention under investigation and drop out 
when allocated to the control arm. Cohort RCTs, as will 
be used in this study, have been adopted to prevent such 
biases.19 20 In this study design, a cohort of people with 
the condition of interest are recruited and consented 
to be approached to complete further questionnaire 
surveys, for their GP medical records and prescriptions to 
be accessed, to be used as a comparator for future studies 
and to be approached for participation in future studies 
if eligible.21 Clinical and patient- reported outcomes are 
captured at regular intervals, allowing those eligible for 
any given study to act as a control without being informed 
about the experimental intervention and thus minimising 
the bias associated with pragmatic trials.
Aims and objectives
The overall purpose is to develop and test the feasibility 
of a nurse- led intervention for people with knee pain 
using a cohort RCT study design.
This study has two phases:
Phase 1 involves the development and evaluation of 
the non- pharmacological treatment component. Specific 
objectives of phase 1 are to: (1) develop a training package 
for nurses to deliver the core non- pharmacological and 
pharmacological principles to manage knee OA as recom-
mended by NICE; (2) determine the fidelity of delivery 
of the nurse- delivered components of the intervention; 
(3) explore patient and nurse acceptability of the non- 
pharmacological components of the intervention.
Phase 2 will test the feasibility of a cohort RCT of 
nurse- led versus usual care of people with knee pain and 
explore whether such a trial should provide analgesia 
before non- pharmacological interventions.
METHODS
Participants
Participants eligible for both phases of the study will be 
aged 40 years or older and self- reporting knee pain on 
most days of the previous month for at least 3 months. 
Knee pain severity will be scored between 4 and 7 on a 
0–10 numeric rating scale (NRS). This will be assessed 
using the following question: ‘Over the past 4- weeks, how 
intense was the average pain or aching in your knees on 
a 0–10 scale, where 0 is no pain and 10 is pain as bad as 
could be?’
Exclusion criteria include participants who are unable 
to communicate in English, who are housebound or care 
home residents, on dialysis or home oxygen, pregnant or 
have dementia, serious mental illness, terminal cancer, 
autoimmune rheumatic diseases, asthma or lung disease 
requiring regular daily oral corticosteroids, unstable 
angina or heart failure, known peripheral vascular 
disease, stroke with residual weakness or sensory loss, 
physician- diagnosed peripheral neuropathy with sensory 
or motor deficit, previous knee or hip replacement, on a 
waiting list for a knee or hip replacement or with severe 
knee pain (score >7 on NRS for average pain in the past 
4 weeks).
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Nurses who undergo the intervention training and 
delivered the intervention in the study will be recruited to 
the qualitative components of the study and will give their 
consent to be interviewed in both phases of the study.
Recruitment
There are three routes of recruitment:
1. Participants will primarily be recruited from the 
Investigating Musculoskeletal Health and Wellbeing 
survey (NCT03696134), a cohort study that aims to 
measure and characterise the development and pro-
gression of pain, frailty and disability and form a lon-
gitudinal context for nested research.21 Participants 
who self- report knee pain as their predominant body 
pain and consent for future research contact will be 
sent a questionnaire enquiring about their knee pain, 
mood, function and quality of life. They will also be 
asked about willingness to receive information about 
trials on knee pain, complete further questionnaires 
on knee pain, and for their data to be used for compar-
isons with other participant groups in research studies. 
Those willing and meeting the eligibility criteria will 
be invited to take part in the current study (figure 1).
2. Additional participants identified by screening of GP 
records for previous consultation for knee pain will be 
sent a questionnaire as outlined above.
3. Finally, people with knee pain or OA who have taken 
part in previous community- based surveys in Academic 
Rheumatology, University of Nottingham and consent-
ed for future research contact may be approached with 
a questionnaire.
Setting
Study visits for research assessment will occur at 
Academic Rheumatology, City Hospital Nottingham, UK 
and the David Greenfield Unit, Queen’s Medical Centre, 
Nottingham, UK. The intervention will be delivered at 
Academic Rheumatology, City Hospital Nottingham.
Consent and withdrawal
All participants will give written informed consent before 
entering the study and before any assessments or inter-
ventions related to the study are undertaken. Optional 
consent will be sought for video recording of the inter-
vention sessions to evaluate fidelity and audio recording 
of participant interviews. Participants will be free to with-
draw at any time if they desire to do so, or at the discre-
tion of the chief investigator. In the event of withdrawal, 
any data collected up until that point will be kept and 
potentially included in any analyses.
Patient and public involvement
The design of this study was supported by a patient advi-
sory group of three people with hip or knee OA and a 
range of experiences in primary and secondary care. The 
group recognised the challenges of providing full expla-
nations and individualised advice in a time- limited GP 
consultation and agreed that a wholly nurse- led interven-
tion would be acceptable or preferable to most people. 
They provided input into the content of the both phar-
macological and non- pharmacological components, the 
number and length of intervention sessions and the use 
of exercise diaries and educational content.
PHASE 1: DEVELOPMENT OF THE NON-PHARMACOLOGICAL 
COMPONENT
The non- pharmacological intervention will be devel-
oped according to the Medical Research Council frame-
work for developing complex packages of care.22 It was 
informed by several strands of evidence including current 
guidelines, an expert multidisciplinary team of physio-
therapists, rheumatologists and nurses, patient opinion, 
physiological considerations and behaviour change 
theory.
In brief, the intervention consists of a holistic assess-
ment of the participant, individualised education about 
OA, aerobic and strengthening exercises and weight loss 
advice if required. Evidence- based strategies to motivate 
participants and support adherence to healthy behaviours 
will be employed.
The training package
A training package for nurses will be developed and piloted 
during this phase. Research nurses will be recruited 
Figure 1 Participant timeline through the study. GP, general 
practitioner; IMHW, Investigating Musculoskeletal Health and 
Wellbeing cohort study; OA, osteoarthritis; RCT, randomised 
controlled trial.
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without any prior knowledge of treating musculoskeletal 
conditions. The content will be based on current NICE 
guidelines for the management of OA5 and a report by 
Arthritis Research UK on the educational needs of health 
professionals working with people with OA.23 Academic 
and clinical experts and members of a patient and public 
involvement group have provided input into the training 
package.
Delivery of the training package will be underpinned by 
educational theory24 and will build on the nurses existing 
knowledge of the condition. Training will be deliv-
ered in face- to- face sessions, complemented by a range 
of learning resources including a manual, case studies, 
online resources and patient simulations. Key compo-
nents of the training will include:
 ► The epidemiology and nature of knee pain and knee 
OA.
 ► Assessment of the patient with knee OA.
 ► Core NICE guidelines for managing OA.
 ► Principles of strengthening and aerobic exercise 
prescription for knee OA.
 ► Information and advice to support weight loss.
 ► Strategies to support behaviour change.
 ► Pharmacological management of OA and knee pain 
following a stepwise protocol of optimising analgesia.
Study design
A pre- post intervention study using mixed quantita-
tive and qualitative methods to determine the fidelity 
of delivery and the acceptability of the intervention by 
patients and nurses. After the nurse training, 20 partici-
pants with knee pain will be recruited to this study. They 
will receive the non- pharmacological components of the 
intervention covering as described above in four sessions 
over a 5- week period.
Quantitative methods
Fidelity of delivery refers to the assessment of whether 
content of the sessions was delivered as intended. This 
will be assessed using a priori fidelity checklist of five 
to eight categories and individual components (online 
supplementary additional file 1). Categories included 
materials, introduction, assessment, education, exercise, 
weight loss, adjunct treatments, and review and planning. 
All interventions in this phase will be video recorded 
(with consent). Nurses will self- complete the checklist 
after each session and a researcher will independently 
complete the checklist using the video recordings. The 
individual components of each category for each session 
will be rated as being complete, partially complete, not 
completed or not applicable. A sample of video record-
ings will be reviewed by a second researcher to determine 
inter- rater reliability.
Quantitative analysis
Fidelity scores will be presented as the percentage of 
components that were delivered as intended for the 
overall delivery of the intervention, for each session and 
for each category. Inter- rater reliability between the two 
researchers scoring the video recordings will be reported, 
as will the level of agreement between nurse- completed 
scores and researcher- completed (video) scores. For 
delivery of complex interventions such as this, levels of 
fidelity have been previously interpreted as ‘high’ fidelity 
where 80%–100% of the specified components were 
delivered as intended, ‘moderate’ 51%–79% and ‘low’ 
0%–50%.25 Where the fidelity scores are less than 80%, 
we will explore further to establish which components are 
responsible.
Qualitative methods
Acceptability of the intervention will be explored in a 
face- to- face interview with all participants who received 
the intervention. Participants who withdraw from the 
intervention will be offered the opportunity to take part 
in an interview to explore their experiences and reasons 
for discontinuation. The nurses who deliver the interven-
tion will also be invited to interview, to explore their views 
on the training, experience in delivering the intervention 
and perceived factors influencing the fidelity of delivery. 
Interviews will be carried out by a PhD student (PAN) and 
overseen by two experienced qualitative researchers (AF 
and RdN). All interviews will be audio recorded and tran-
scribed verbatim by an external specialist company Tran-
scribe It and anonymised.
Qualitative analysis
After data transcription, all data will be checked for accu-
racy before transcripts are imported to NVivo V.12. Quali-
tative data will be analysed using a framework approach.26 
This method sits within the broad family of thematic 
analysis, but is particularly useful for research that has 
specific questions and a priori issues that need to be dealt 
with.27 The analysis will follow the five stages of frame-
work analysis: familiarisation with the data, construction 
of an initial thematic framework, indexing and sorting 
the data using initial thematic framework, finalisation 
of thematic framework, and summarising and displaying 
the data into a matrix. Emergent themes and subthemes 
will be discussed and agreed by at least two researchers to 
increase the validity of the analyses.
Following the fidelity evaluation and qualitative inter-
views, modifications may be made to study materials, 
procedures or protocol, and/or nurse training.
PHASE 2: FEASIBILITY COHORT RCT
Trial design
This will be a single- centre, mixed methods feasibility 
cohort RCT. Participants will be recruited as described 
above and randomised to one of three treatment arms 
(figure 1).
Group A will receive the non- pharmacological protocol 
for 13 weeks followed by the pharmacological protocol 
between weeks 13 and 26 as required.
 o
n
 Septem
ber 15, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2020-037760 on 9 September 2020. Downloaded from 
5Hall M, et al. BMJ Open 2020;10:e037760. doi:10.1136/bmjopen-2020-037760
Open access
Group B will receive the pharmacological protocol in 
the first 13 weeks followed by the non- pharmacological 
protocol between weeks 13 and 26 with optimised back-
ground analgesia.
Group C is a control (cohort) group and will continue 
to receive usual care.
Randomisation and allocation concealment
Participants will be individually randomised on a 5:5:1 
ratio using randomly permuted block sizes of 3 and 6, 
stratified for the number of eligible knees (ie, unilateral or 
bilateral knee pain). Randomisation codes will be gener-
ated by the study statistician. Allocations to groups will be 
enclosed in serially numbered, opaque, sealed envelopes 
with a carbon copy paper. The serially numbered opaque 
envelopes will be packaged and prepared by an indepen-
dent member not belonging to the research team. Partic-
ipants will be randomised by the trial coordinator who 
will ensure that the envelopes are opened sequentially, 
and only after the participant’s unique study identifier is 
written on the outside of the appropriate envelope.
Blinding
It is not possible to blind the study participants or the 
nurse delivering the intervention to the group alloca-
tions. However, study personnel involved in outcome 
assessment and data analysis will be blinded. Participants 
will be requested not to disclose group allocation to the 
outcome assessor, but if this does occur it will be recorded. 
Only once data have been cleaned and analysed will the 
treatment allocation be made known.
Intervention
The intervention will be delivered by the same nurse as in 
phase 1, any additional nurses recruited will undergo the 
same training.
Non-pharmacological component
The non- pharmacological component will be deliv-
ered by a nurse as detailed in table 1 incorporating any 
modifications made following the development phase (a 
detailed description is included in online supplementary 
additional file 2). It will be delivered in up to six face- 
to- face sessions over 13 weeks. Participants will continue 
their usual analgesics in this period.
Pharmacological component
The nurse will take a history of current symptoms, comor-
bidities, medications and the main knee complaint of the 
participant. They will be advised by the nurse to continue 
on their current analgesia prescribed by their GP, and 
to add in simpler and safer analgesics in the sequence 
shown in figure 2. Once they are on a simpler and safer 
analgesic, they will be advised to reduce the dose of poten-
tially more toxic or stronger analgesic. However, this will 
depend on the subjective improvement the participant 
experiences with simpler analgesic.
Relative and absolute contraindications will be assessed 
against a checklist developed from the British National 
Formulary. Participants with absolute contraindication 
to an analgesic will not be prescribed that drug. Partici-
pants with relative contraindications may be prescribed 
the aforementioned drug if they are willing to do so after 
exploring risks and benefits.
Analgesics will be reviewed at two weekly intervals over a 
13- week period and optimised if the pain relief is insuffi-
cient. This will be done over the phone, or at a face- to- face 
visit, depending on participant preference. The visits and 
telephone consultations will be conducted by the nurse 
and prescriptions signed by the principal investigator or 
nominated deputy. Once a participant achieves adequate 
pain control and does not request any further changes to 
their analgesia, they will be advised to contact the nurse 
by phone for changes to their treatment if needed during 
the study.
Usual care
Participants allocated to this group will continue to receive 
usual care for their knee pain. They will not undertake 
any of the clinical assessments and will not receive any 
input from the nurse. People in this group will be part of 
the baseline cohort and will not be aware of the content 
of the invention groups.
Concomitant treatments
Participation in the trial does not preclude the partici-
pants from receiving any concomitant care or treatment.
Quantitative study outcomes
The feasibility of running a full trial will be assessed by 
recording the following data:
 ► Recruitment rates.
 ► Dropout rate and reasons for dropout.
 ► Number of scheduled nurse appointments attended.
 ► Number of instances of unblinding.
 ► Completeness of questionnaire data.
 ► Concordance with exercise assessed using data from 
participants’ exercise diaries (total number of days on 
which exercises were performed).
Participant-reported measures
A summary of all participant outcomes to be collected at 
0, 13 and 26 weeks for groups A and B is presented in 
table 2 and in online supplementary additional file 3.
Group C will receive a questionnaire at week 26, 
enquiring about healthcare utilisation, demographic 
characteristics, self- reported height, self- reported 
weight, current alcohol intake and smoking status, 
comorbidities, medications, joint pain, central aspects 
of pain in knee scale, Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC), Short 
Form-36 Health Survey version 2 and Hospital Anxiety 
and Depression Scale.
Safety and adverse events
This study intervention follows the current NICE guide-
lines that might be offered as part of routine clinical 
care. As such the risk of severe or unexpected adverse 
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events (AE) is low.28 Exercise and an increase in phys-
ical activity may initially increase the risk of AEs such 
as pain, fatigue or muscle soreness or increased falls 
through increased activity. To reduce the risk of AEs 
the exercise programme will be tailored to the abili-
ties of the participants. All serious and non- serious AEs 
will be monitored and recorded through the study by 
the nurses and will be managed in line with current 
National Institute for Health Research guidelines.29
Qualitative study outcomes
Acceptability of the intervention will be assessed using 
qualitative interviews conducted after the interven-
tion (week 26) with approximately 10 participants 
Table 1 Content of non- pharmacological component of intervention
Content of non- pharmacological component
Session
1 2 3 4 5 6
Assessment             
  Holistic assessment including symptoms, pain elsewhere, comorbidities, impact 
on function, occupation, mood, sleep, illness perceptions, current levels of PA and 
attitudes to PA and weight loss (if required)
✓           
  Physical assessment of knee range of movement, lower limb muscle strength, 
observation of gait and functional activities, BMI
✓           
Education and advice             
  Provision of Arthritis Research UK booklet
  ‘Osteoarthritis of the knee’
✓           
  Nature of osteoarthritis ✓           
  Adverse illness perceptions addressed ✓           
  Core treatments ✓           
  Benefits of exercise and PA ✓           
  Pacing ✓           
  Benefits of weight loss (if required) ✓           
  Use of heat and cold for pain ✓           
  Appropriate footwear, use of walking aids ✓           
  Signposting to further information if required ✓           
  Review of above if required   ✓ ✓ ✓ ✓ ✓
Exercise (individualised programme)             
  Strengthening exercise ✓           
  Aerobic exercise/PA ✓           
  Functional exercises ✓           
  Stretching exercises ✓           
  Review performance of exercise   ✓ ✓ ✓ ✓ ✓
  Progression/regression of exercises   ✓ ✓ ✓ ✓ ✓
Weight loss (if required)             
  Previous efforts to lose weight discussed ✓           
  Strategies for weight loss discussed ✓           
  Agree weight loss goal (5% body weight) ✓           
  Signposting to resources (weight loss groups, NHS weight loss plan) ✓           
  Review of weight loss progress and advice   ✓ ✓ ✓ ✓ ✓
Adherence/behaviour change strategies             
  Patient goals and action plan recorded for exercise and weight loss ✓ ✓ ✓ ✓ ✓ ✓
  Patient’s confidence to achieve goals discussed and recorded ✓ ✓ ✓ ✓ ✓ ✓
  Barriers and facilitators discussed ✓ ✓ ✓ ✓ ✓ ✓
  Exercise diary completed and discussed ✓ ✓ ✓ ✓ ✓ ✓
BMI, body mass index; NHS, National Health Service; PA, physical activity.
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from each of the intervention arms (groups A and B). 
They will be purposively selected to represent those 
with likely low and high concordance with the exercise 
advice using the Adherence to Exercise Scale for Older 
Patients questionnaire. Interviews will explore partici-
pants’ overall satisfaction with the intervention and the 
sequence of treatment, perceptions of nurse- led care 
and previous treatment experience, level of adherence 
to the advice, perceptions of managing their knee pain, 
as well as perceived impact of their knee pain on their 
daily life before and after the intervention. Participants 
who withdraw from the intervention will be offered the 
opportunity to take part in an interview. Interviews will 
also be conducted with the study nurses to explore their 
experience in delivering the intervention, perceived 
effectiveness of the intervention and barriers to imple-
mentation and how these may be overcome.
Sample size
Quantitative study
As this is a feasibility study, a formal sample size calcu-
lation for between- group comparisons of primary clin-
ical outcome is not appropriate. A target sample size of 
53 participants per arm will be sought over the recruit-
ment period to reliably estimate the feasibility outcomes 
relating to recruitment and retention rates to inform a 
fully powered RCT. With a sample size of 159 (53 partic-
ipants per arm), we will be able to estimate a dropout 
rate of no more than 20% to within 7% points of the 
true value with 95% confidence.
Qualitative study
Target recruitment will be 20 participants, 10 from 
each intervention arm. However, final numbers will be 
determined by data saturation, where no new themes 
are identified.
Data analysis
Feasibility outcomes will be estimated using descriptive 
statistics (with 95% CIs) and will be presented overall 
and per randomised groups. A Consolidated Standards 
of Reporting Trials (CONSORT) diagram will summarise 
the flow of participants through the study. Reasons 
for non- eligibility, withdrawals and non- completion of 
follow- up questionnaires will be presented if available. 
As this is a feasibility study, interim analyses are not 
planned. Similarly, missing data will not be imputed; on 
the contrary, the pattern of missing data will be assessed. 
Protocol non- adherence will be assessed as randomised.
Quantitative analysis
The main quantitative analysis will be of the trial feasi-
bility outcomes:
 ► Recruitment rate (per month, per recruitment source, 
per 100 participants approached).
 ► Dropout rate (per arm, per stage pharmacological/
non- pharmacological).
 ► Attendance rates for scheduled nurse appointments.
 ► Missing data.
 ► Power and sample size calculation for a definitive 
trial will be based on WOMAC summated knee pain 
domain scores in the most painful knee at week 26.
Descriptive statistics will be presented for demographic 
data and all baseline clinical outcome measures. Explor-
atory analysis of clinical outcomes will be conducted 
according to randomised groups but will not be interpreted 
in terms of effectiveness. The emphasis will be on CIs of 
effect size estimations rather than the p values. Changes 
Figure 2 Analgesic sequence for pharmacological component. NSAID, non- steroidal anti- inflammatory drug.
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in clinical and patient- reported outcomes from baseline to 
13 and 26 weeks will be analysed using appropriate para-
metric or non- parametric statistics. A comparison of those 
receiving the pharmacological component first with those 
receiving the non- pharmacological component first will 
help determine the order of delivery in a future trial.
Qualitative analysis
Interview data will be analysed following the frame-
work approach as described in phase 1.30 Analysis will 
be conducted in parallel with the interviews and initial 
results will inform subsequent sampling and areas of 
interest to follow- up.
CRITERIA FOR TERMINATING THE STUDY
The study may be stopped by the sponsor if there is 
apparent futility in continuing with it.
DATA MANAGEMENT
Study data will be managed by the study coordinator 
(BM) under the supervision of the chief investigator 
(AA) and the study statistician (RO). A data monitoring 
committee has not been convened by the sponsor as this 
is a feasibility study using well- established and NICE- 
approved interventions. All trial staff and investigators 
will endeavour to protect the rights of the trial’s partic-
ipants to privacy and informed consent, and will adhere 
to the Data Protection Act 2018 and the General Data 
Protection Regulation (European Union) 2016/679. The 
study coordinator shall carry out monitoring of trial data 
as an ongoing activity. Trial data and evidence of moni-
toring and systems audit will be made available for inspec-
tion as required by the sponsor and the Research Ethics 
Committee (REC).
Table 2 Summary of questionnaire and research measures to be collected
Domain Data source Measure/instrument
Time points
(week)
Demographic 
characteristics
Research assessment Age, height, weight 0
0,13,26
Comorbidities and 
medications
Research assessment Comorbidities, current medications 0
0,13,26
Radiographic 
evaluation
Research assessment Bilateral knee radiographs: PA semiflexed weight bearing and skyline 
views37 scored for Kellgren and Lawrence grades and using the 
Nottingham line drawing atlas38
0
Knee pain Self- report Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC)39
0,13,26
  Self- report Analgesic and NSAID consumption 0,13,26
  Research assessment Quantitative sensory testing* including pressure pain detection 
threshold, temporal summation and conditioned pain modulation
0,13,26
Physical activity Self- report International Physical Activity Questionnaire (IPAQ)40 0,13,26
Function Self- report WOMAC function subscale39 0,13,26
  Research assessment Timed Up and Go (TUG) test41
30 s chair stand test42
0,13,26
Muscle function Research assessment Isometric and isokinetic quadriceps strength* 0,13,26
Quality of life Self- report The Short Form-36 Health Survey V243
EQ- 5D- 5L44
0,13, 26
Psychological 
wellness
Self- report Hospital Anxiety and Depression Scale (HADS)45 0,13,26
Healthcare use Self- report Service use questionnaire to assess use of NHS or private healthcare, 
prescription and over- the- counter medicines related to knee pain 
outside of the study
0,13,26
Participant 
engagement in 
treatment
Nurse- completed 
questionnaire
Pittsburgh Rehabilitation Participation Scale (PRPS)46 13/26†
Exercise adherence Self- report Adherence to Exercise Scale for Older Patients (AESOP)47 13/26‡
Acceptability of 
intervention
Self- report Participant satisfaction with treatment 13,26
Blood markers Research assessment Non- fasting serum cholesterol, HbA1c and C- reactive protein§ 0,13,26
Safety Case report form Adverse events 26
*Further description included in detail in online supplementary additional files 3 and 4.
†This will be completed by the nurse after each of the non- pharmacological sessions.
‡This will be completed by the participant at the end of non- pharmacological arm.
§Online supplementary additional file 4.
EQ- 5D- 5L, 5- level version of EuroQol-5 Dimension; NHS, National Health Service; NSAID, non- steroidal anti- inflammatory drug; PA, physical activity.
 o
n
 Septem
ber 15, 2020 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2020-037760 on 9 September 2020. Downloaded from 
9Hall M, et al. BMJ Open 2020;10:e037760. doi:10.1136/bmjopen-2020-037760
Open access
Qualitative data and video or audio recordings will be 
archived in the University of Nottingham servers using 
password protection. Quantitative trial data will be stored 
in Research Electronic Data Capture database with range 
checks for data values. All quantitative data will be source data 
verified. Ten per cent of the entered trial data will be audited 
and variables for which there is >5% error will be entered 
again. Once auditing is complete the electronic case report 
forms will be signed off and the database placed under hard 
lock. Study data will be available to the study statistician, PhD 
student and research fellow working on the project.
In compliance with the International Conference on 
Harmonization/Good Clinical Practice guidelines, regula-
tions and in accordance with the University of Nottingham 
Research Code of Conduct and Research Ethics, the chief 
or local principal investigator will maintain all records and 
documents regarding the conduct of the study. These will be 
retained for at least 7 years or longer if required.
ROLE OF SPONSOR AND FUNDERS
There is no role of the study sponsors and funders in the 
design; collection, management, analysis and interpretation 
of data; writing of the report; and the decision to submit the 
report for publication. The study sponsor and funder will 
have no ultimate authority over any of these activities.
ETHICS AND DISSEMINATION
This protocol was given approval approved by the East 
Midlands- Derby REC (18/EM/0288) prior to commencing 
recruitment in November 2018 which is ongoing. The study 
was registered at  ClinicalTrials. gov. The trial will be reported 
according to CONSORT guidance and standards.31 The 
results will be submitted for publication in peer- reviewed 
academic journals. Any modification to the approved 
protocol will result in resubmission to gain approval from 
the REC and study sponsor. Authorship eligibility guidelines 
will be adhered to, and we do not intend to use professional 
writers. Any interested researcher will be able to access the 
full protocol, participant- level data set and statistical code for 
research purposes after data sharing agreement has been 
signed.
DISCUSSION
People with knee OA continue to often receive suboptimal 
fragmented care and the core NICE recommendations 
are underused in primary care.32 Given that knee pain is 
common, and there is a huge time pressure on GPs in the 
UK, it is vital to find out if a complex package of care incorpo-
rating the core recommendations can be delivered by other 
healthcare professionals such as practice nurses.
We believe that a wholly nurse- led management programme 
where a nurse acts as the point of contact for people with knee 
pain due to OA, educates them about the condition, provides 
core pharmacological and non- pharmacological treatments 
and builds a long- term therapeutic relationship is likely to be 
clinically effective and cost- effective in improving quality of 
OA care as demonstrated for other chronic conditions.16 33–36
This study will not provide an answer as to the effective-
ness of a wholly nurse- led intervention for OA and knee pain, 
but will determine the feasibility of implementing this model 
of care and of testing it in a full trial using practice nurses. 
Assessing fidelity will play an important part in the develop-
ment and evaluation of the intervention, by exploring the 
extent to which the nurses can deliver individual components 
of the complex package of care for knee pain as planned. 
Combined with qualitative interviews to explore their accept-
ability, this will provide insight into the suitability of the 
training and intervention to inform appropriate refinements 
to the whole package of care that can be tested in a full trial. 
Although the intervention will take place in a research setting 
rather than primary care, the study outcomes will provide 
insight into the feasibility of implementation into real- world 
practice.
Further, this study will explore at what point analgesia 
should be optimised within this complex package of care. 
Having two intervention groups, one where analgesia is 
provided before the non- pharmacological component and 
one where it is provided after, will help us determine whether 
patients exercise better when analgesia is optimised first, or 
whether they are able to exercise sufficiently before this. This 
will inform the order of treatment in a two- arm full trial.
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